Journal article
Donepezil for dementia due to Alzheimer's disease
- Abstract:
-
Background Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. This can be done by a group of drugs known as cholinesterase inhibitors. Donepezil is a cholinesterase inhibitor.
This review is an updated version of a review ... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.6MB, Terms of use)
-
- Publisher copy:
- 10.1002/14651858.cd001190.pub3
Authors
- Publisher:
- John Wiley and Sons, Ltd.
- Journal:
- Cochrane Database of Systematic Reviews More from this journal
- Volume:
- 6
- Issue:
- 1
- Pages:
- Art. No.: CD001190
- Publication date:
- 2018-06-18
- DOI:
- EISSN:
-
1469-493X
- Pmid:
-
29923184
- Language:
-
English
- Pubs id:
-
pubs:859096
- UUID:
-
uuid:04001ef3-178d-4243-a724-7e0d9f79247d
- Local pid:
-
pubs:859096
- Source identifiers:
-
859096
- Deposit date:
-
2018-07-25
Terms of use
- Copyright holder:
- Cochrane Collaboration
- Copyright date:
- 2018
- Notes:
- © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This is the publisher's version of the article. The final version is available online from Wiley at: https://doi.org/10.1002/14651858.CD001190.pub3
If you are the owner of this record, you can report an update to it here: Report update to this record